EQ - NASDAQ
Equillium, Inc.
$3.17
-0.93%Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
At a Glance
Live Snapshoteq
Other Current Liabilities
Last Annual Value
1.82M
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
Equillium, Inc. Competitors Analysis of Other Current Liabilities
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Equillium, Inc. NASDAQ:EQ | 1.82M | -20.7% | -11.7% | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 23.99M | 75.7% | 37.5% | N/A | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 45755.71B | 29164.0% | 2665.6% | 440.1% | |
 CalciMedica, Inc. NASDAQ:CALC | 1.16M | 135.0% | -1.5% | N/A | |
 PDS Biotechnology Corporation NASDAQ:PDSB | -5.16B | N/A | N/A | N/A | |
 Q32 Bio Inc. NASDAQ:QTTB | 3.54M | 5.6% | -20.9% | -4.3% | |
 Century Therapeutics, Inc. NASDAQ:IPSC | 12.13M | 64.5% | 62.2% | N/A | |
 Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO | 1.43M | 39.4% | 64.3% | N/A | |
 Cue Biopharma, Inc. NASDAQ:CUE | 7.63M | 58.5% | 188.3% | 52.9% | |
 OS Therapies Incorporated NYSE:OSTX | 2.35M | -20.7% | 7.8% | N/A | |
 Coeptis Therapeutics, Inc. NASDAQ:COEP | 161.05K | -33.8% | N/A | N/A |
Equillium, Inc. Fair Value Envelope
Related Guides
Continue your EQ research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.